# A Study of Granexin® Gel for the Reduction of Scar Formation in Surgical Wounds Following Bilateral Anchor Incision Breast Surgery

> **NCT04331080** · PHASE2,PHASE3 · COMPLETED · sponsor: **Xequel Bio, Inc.** · enrollment: 184 (actual)

## Conditions studied

- Mammoplasty
- Scarring
- Scar
- Breast Reconstruction

## Interventions

- **DRUG:** Granexin® gel 100 μM
- **DRUG:** Granexin® gel 200 μM
- **DRUG:** Vehicle gel

## Key facts

- **NCT ID:** NCT04331080
- **Lead sponsor:** Xequel Bio, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-01
- **Primary completion:** 2022-05-26
- **Final completion:** 2022-05-26
- **Target enrollment:** 184 (ACTUAL)
- **Last updated:** 2022-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04331080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04331080, "A Study of Granexin® Gel for the Reduction of Scar Formation in Surgical Wounds Following Bilateral Anchor Incision Breast Surgery". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04331080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*